Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06619509 · ClinicalTrials.gov registry record · Phase 2

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

A Phase 2 study of Solid Tumours, sponsored by Boehringer Ingelheim.

Active
Registry status
Phase 2
Development phase
90
Enrollment target
20
Study locations

NCT06619509 is a Phase 2 study of Solid Tumours that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 90 participants, below the 136-participant average among 9 other Solid Tumours trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06619509, a Phase 2 study of Solid Tumours, is active but no longer recruiting, sponsored by Boehringer Ingelheim.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.

Conditions Studied

Solid Tumours

Interventions

  • DRUG Brigimadlin

Study Locations (20)

Other

  • Sanatorio Finochietto - CABA
  • Cliniques Universitaires Saint-Luc - Brussels
  • UZ Leuven - Leuven

California

  • Precision NextGen Oncology - Beverly Hills
  • Sarcoma Oncology Center - Santa Monica

Tennessee

  • West Cancer Center & Research Institute - Germantown
  • Henry-Joyce Cancer Clinic - Nashville

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Mayo Clinic Cancer Center - Jacksonville

Missouri

  • Washington University School of Medicine - St Louis

Nebraska

  • Nebraska Cancer Specialists-Omaha-69066 - Omaha

New York

  • Northwell Health - Lake Success

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-12-30
Est. Completion 2030-12-30
Phase Phase 2

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06619509

The ClinicalTrials.gov registry entry for NCT06619509 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 9 other Solid Tumours trials with a reported enrollment target (34% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 1 intervention - of which Brigimadlin is the first listed.

NCT06619509 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06619509 about?

NCT06619509 is a clinical study titled "A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine". This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was...

What is the current status of trial NCT06619509?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-12-30. Estimated completion is 2030-12-30.

What conditions does trial NCT06619509 study?

This clinical trial studies the following conditions: Solid Tumours.

What interventions are being tested in trial NCT06619509?

The interventions under investigation include: Brigimadlin (DRUG).

Who is sponsoring clinical trial NCT06619509?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06619509 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumours

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumours

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.